RET and thyroid gland papillary carcinoma: RET fusions and mutations, common in medullary and some papillary thyroid cancers, can be effectively treated with selective RET inhibitors such as selpercatinib and pralsetinib, which have demonstrated high response rates and favorable tolerability compared to older multikinase inhibitors.